The French Big Pharma is paying SK Chemicals $23 million up front, after which both companies will invest in the project.
What does $190 million in R&D spending get you? In the case of Alder Biopharmaceuticals, it got a blockbuster $1.35 billion development deal with Bristol-Myers Squibb and an in-house migraine drug headed into a Phase IIb study. It also takes the biotech to the threshold of an IPO it detailed today, which is designed to raise $115 million to fund operations through 2015.
Diagnostics maker Corgenix revealed that it might offer itself up as an M&A target, which is one of several options the small-but-growing outfit is exploring in an effort to boost its shareholder value in 2014.
PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.
Waters Corp. inked a research partnership deal with an Irish research facility targeted toward developing a blood-based biomarker test that can predict whether a fetus is at high risk for premature birth.
Tesaro is making a move into the hot cancer immunotherapy field, paying $17 million upfront and offering milestones worth hundreds of millions more to work with AnaptysBio on a portfolio of antibodies that could be used in combination with its own pipeline drugs. And while one of the targets is PD-1, a popular subject in a field now dominated by Bristol-Myers Squibb and Merck, a pair of less familiar targets is also included in the package.
Fresh off scoring U.S. certification for its genomics lab, China's WuXi PharmaTech is amping up its lab testing services, buying into Illumina's $1,000 genome technology and teaming up with Pacific Biomarkers to broaden its assay menu.
Caisson Biotech, which signed on with Novo Nordisk in 2012 for the development of drugs using Caisson's delivery platform HEPtune, expanded the scope of the deal to cover specific indications, including its approach to insulin delivery.
Sanofi is joining forces with UCB to study new small-molecule approaches to treating inflammatory conditions like arthritis, looking for an easier form of administration to some of the blockbuster injected biologics that dominate the field. The pharma giant is ready to spend more than $138 million for a package of milestones and an upfront payment to UCB in exchange for the partnering arrangement with its NewMedicines research arm.
Eventual winner Johnson & Johnson wasn't Pharmacyclics' first choice to partner with on ibrutinib, CEO Robert Duggan told FierceBiotech in January, but, as The Wall Street Journal lays out, J&J and its expansive approach to dealmaking won out in the end.